Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. (HOWL) priced its initial public offering on Apr 30, 2021 at $16.00 per share, within its $15.00–$17.00 range, raising $120M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $440.6M. Jefferies was lead-left underwriter, joined by Leerink Partners, Evercore ISI and H.C. Wainwright. WilmerHale advised the company and Cooley advised the underwriters.

Werewolf Therapeutics, Inc. is a biopharmaceutical company developing cancer immunotherapies on its PREDATOR platform. Its INDUKINE molecules activate selectively in the tumor microenvironment, and the lead candidates are WTX-124 (IL-2) and WTX-330 (IL-12).

Status

IPO

Ticker

HOWL

Exchange

Nasdaq Global Select

Priced

Apr 30, 2021

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$120M

Market cap at IPO price

$440.6M

First filed

Apr 8, 2021

Underwriters

Jefferies, Leerink Partners, Evercore ISI and H.C. Wainwright

Company counsel

WilmerHale

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.